Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation

PURPOSE: Trastuzumab emtansine (T-DM1) is the standard treatment in the current second-line therapy of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. However, a useful therapy after T-DM1 resistance has not been established. In this study, we established two diffe...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer Chemother Pharmacol
Auteurs principaux: Yamashita-Kashima, Yoriko, Shu, Sei, Osada, Masahiro, Fujimura, Takaaki, Yoshiura, Shigeki, Harada, Naoki, Yoshimura, Yasushi
Format: Artigo
Langue:Inglês
Publié: Springer Berlin Heidelberg 2020
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7561595/
https://ncbi.nlm.nih.gov/pubmed/32997196
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-020-04138-5
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires